Mark Ciaccio, PhD, is a seasoned professional in artificial intelligence applications for clinical trial operations, currently serving as a Senior Scientist II at AbbVie. They founded Microwestern Life Sciences in 2015 and previously held positions at notable institutions including the University of Chicago and Schering-Plough Research Institute. With a PhD in Cellular and Molecular Physiology from the University of Chicago and a B.S. in Biochemical Engineering from the University of Notre Dame, Mark’s work focuses on employing advanced AI to accelerate drug development and improve human health.
This person is not in any teams
This person is not in any offices